Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases (COOX)

Boston Children's Hospital

Status: Completed

Conditions: Asthma; Allergic Rhinitis; Cystic Fibrosis; Pneumonia

Study type: Observational

Funder types: Other

Identifiers

NCT02831348

ChildrenH

Details and patient eligibility

About

This is a pilot cross-sectional study of measured transcutaneous CO-oximetry in children with inflammatory and non-inflammatory conditions.

Full description

Children and young adults age 6-24 with the following conditions: asthma, pneumonia, allergic rhinitis, cystic fibrosis, and well child (without inflammatory illness) will be recruited.

Subjects will be asked to complete a brief screening survey to determine if they meet inclusion criteria. Enrolled subjects will be asked to complete questionnaire forms to characterize their health, current symptoms, medications, and common exposures. Transcutaneous carboxyhemoglobin will be recorded.

This study is cross-sectional and will only require one visit coinciding with the clinical visit. Analysis will determine the pairwise differences in SpCO between conditions tested.

Enrollment: 59 patients

Sex: All

Ages: 6 to 24 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• diagnosis of asthma, pneumonia, allergic rhinitis, or none of the previous (control group)
• Ability to complete study procedures

Exclusion criteria

• Cardiopulmonary disease outside of the specific conditions for inclusion
• Prematurity
• Congenital heart disease
• Current diagnosis of more than one of the following: asthma, pneumonia, allergic rhinitis, cystic fibrosis, or - for controls - any current infection
• Recent serious bacterial infection (except for pneumonia in the pneumonia group)
• Concurrent clinical chest X-ray with findings other those that expected for the group (i.e. normal chest X-ray in pneumonia group or suspected pneumonia on chest X-ray in asthma group). To be determined by attending radiologist's interpretation.

Trial design

59 participants in 8 patient groups

Uncontrolled asthma

Description:

Indicated by an asthma control test (ACT) score of \<20 and asthma symptoms of cough, wheeze, or chest tightness for more than 2 days in the prior 2 weeks, OR current asthma exacerbation indicated by the prescription of a short course (3-5 days) of systemic corticosteroids by treating provider at the time of visit.

Controlled asthma

Description:

Indicated by an ACT score of \>19, or spirometry results within 10% of year's best value (based on FEV1).

Pneumonia

Description:

Indicated by an admission diagnosis of pneumonia with chest X-ray consistent with the diagnosis, based on attending radiologist's interpretation.

Controlled allergic rhinitis

Description:

Indicated by a rhinitis control assessment test (RCAT) score of \>= 21.

Uncontrolled allergic rhinitis

Description:

Indicated by an RCAT score of \<21.

Cystic fibrosis (exacerbated)

Description:

Indicated by treating physician's assessment of cystic fibrosis respiratory exacerbation within 24 hours of initial antibiotic therapy.

Cystic fibrosis (stable)

Description:

Indicated by diagnosis of cystic fibrosis with baseline symptoms and with spirometry results (based on FEV1) within 5% of year's best value.

Control

Description:

Indicated by a negative history of any of the conditions characterizing the other groups.